Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.4%

1 terminated/withdrawn out of 29 trials

Success Rate

96.2%

+9.6% vs industry average

Late-Stage Pipeline

17%

5 trials in Phase 3/4

Results Transparency

36%

9 of 25 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 2

10(34.5%)

Phase 1

9(31.0%)

N/A

5(17.2%)

Phase 3

4(13.8%)

Phase 4

1(3.4%)

29Total

Phase 2(10)

Phase 1(9)

N/A(5)

Phase 3(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT07060508Phase 2Completed

L9LS in Women of Childbearing Potential in Mali

Role: collaborator

NCT05155579Phase 1Completed

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Role: collaborator

NCT06080243Phase 2Active Not Recruiting

Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali

Role: collaborator

NCT04704830Phase 3Active Not Recruiting

R21/Matrix-M in African Children Against Clinical Malaria

Role: collaborator

NCT06413108Phase 1Completed

Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali

Role: collaborator

NCT05304611Phase 2Completed

Anti-malaria MAb in Malian Children

Role: collaborator

NCT00126971Phase 1Terminated

Chlorproguanil-Dapsone in Pregnant Women

Role: collaborator

NCT04329104Phase 2Completed

Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali

Role: collaborator

NCT05816330Phase 2Completed

L9LS MAb in Malian Adults

Role: collaborator

NCT04319380Phase 3Completed

Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study

Role: collaborator

NCT05135273Phase 1Completed

Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali

Role: collaborator

NCT04795648Not ApplicableCompleted

Spatial Repellents for Vector Control

Role: collaborator

NCT03989102Phase 2Completed

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali

Role: collaborator

NCT04940130Phase 2Completed

PfSPZ Vaccine Trial in Malian Children

Role: collaborator

NCT02694055Not ApplicableCompleted

Trial of Proactive Community Case Management to Reduce Child Mortality

Role: collaborator

NCT05776017Phase 1Unknown

MSP3-CRM-Vac4All/ Alhydrogel® Vaccine

Role: collaborator

NCT03143218Phase 3Completed

Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)

Role: collaborator

NCT03510481Phase 1Completed

Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali

Role: collaborator

NCT04049916Phase 2Completed

Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission

Role: collaborator

NCT01988636Phase 1Completed

Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults

Role: collaborator